Robotic-Assisted Lung Transplant Completed

Robotic-Assisted Surgery Means Less Pain and Quicker Healing for Patients

Robotic-Assisted Lung Transplant: Cardiothoracic surgeons in the Smidt Heart Institute at Cedars-Sinai recently performed a groundbreaking robotic-assisted lung transplant.

With a new right lung, the patient, a 69-year-old man from Claremont, California, is back to exercising and chasing his grandchildren after eight years of declining health and mobility as well as breathing difficulties.

View video here.

“We believe robotic-assisted surgery is the future of lung transplantation,” said Dominic Emerson, MD, the lead surgeon and associate surgical director of Heart Transplant and Mechanical Circulatory Support in the Smidt Heart Institute.

“Over the past two years, we have transitioned from offering traditional lung transplantation to minimally invasive lung transplantation to now, robotic-assisted capabilities. This long-awaited achievement is the start of a new era of cardiothoracic care.”

Prior to pioneering the world’s first robotically assisted lung transplant, surgeons in the Smidt Heart Institute also developed new, minimally invasive techniques that speed healing and shorten hospital stays.

“Our team pioneered the utilization of smaller incisions for lung transplant, so much so that most incisions are no bigger than the short side of a driver’s license,” said Emerson, an assistant professor of cardiac surgery. “Smaller incisions reduce postoperative pain and improve recovery for our patients.”

Unlike routine lung transplantations, where surgeons usually create a “clamshell” incision which involves cutting apart the breastbone, the Smidt Heart Institute developed a technique requiring only a small incision between the ribs—just large enough to remove a patient’s old, deflated lungs and then, insert and inflate the new donor lungs.

In addition to this technique, during the robotic lung transplant, surgeons used the robotic device to enter the body via two small “portholes” on the side of the body. These small portholes are utilized during all lung transplant surgeries to place chest drains at the end of surgery, which are later removed.

Pedro Catarino, MD “With the robotic surgery, we still make the same incisions we make for our minimally invasive technique,” said Pedro Catarino, MD,  director of Aortic Surgery in the Smidt Heart Institute. “The difference is that instead of a surgeon placing their hands in the incision between the ribs to complete the surgery, the robotic device enters via the portholes.”

 

Catarino, widely recognized as an expert in minimally invasive lung transplantation techniques, scrubbed in alongside Emerson and Dominick Megna, MD, surgical director of the Lung Transplant Program at Cedars-Sinai, to perform the robotic surgery.

The robotic arms, Catarino said, allow for a great deal of movement and manipulation.

“The less movement inside a patient’s body, the less pain there will be post-surgery and the faster recovery times will be,” said Catarino.

In addition to less pain and recovery time for a patient, the robotic procedure has its perks for surgeons, too.

“The visualization used with the robotic device is just so good,” said Emerson. “You can see the airway and blood vessels in ways that are unparalleled. The high-definition, 3-D technology showcases details you would never see normally. It was a remarkable experience—something I will always remember.”

Joanna Chikwe, MD, founding chair of the Department of Cardiac Surgery, noted that the new methods allow the team to help more patients. In 2020, the team performed 18 lung transplants. In 2021, they completed 60.

“Smaller incisions and better visualization lead to better outcomes in the right patients,” said Chikwe. “In addition to surgical advances, we have several research opportunities in the pipeline and plan on big changes in the coming year—changes that will improve every aspect of transplantation for patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”